The international research consortium SGC and SciLifeLab aim to give researchers access to well-validated research tool antibodies.
[by Susanne Gräslund, SGC Karolinska, Helena Persson Lotsholm,DDDP SciLifeLab, Per I Arvidsson, Director DDDP SciLifeLab, Mikael Sundström, Director SGC European activities]
For use as research tools, tens of thousands of antibodies are available on the market, but most of them are not renewable and they are often poorly validated.
Studies on their general performance have shown that less than half of them bind to the target they are supposed to bind to. In turn, this leads to a vast amount of unreliable results, and to research money being spent in vain.
Due to these facts, there is a strong need for well-validated and open access research tool antibodies. To meet this need, the international research consortium SGC has teamed up with the human antibody arm of the national drug discovery plat- form of Science for Life Laboratory (Sci- LifeLab DDDP).
Read the full article from Kemivärlden Biotech Kemisk Tidskrift No 1 2017 as pdf